Xanthine Oxidase Inhibitors in the Management of Gout
|
|
- Benedict Franklin
- 5 years ago
- Views:
Transcription
1 Xanthine Oxidase Inhibitors in the Management of Gout By JAMES B. WYNGAARDEN, M.D. Duke University Medical School The forms of therapy for gout available in the past decade have been very successful in about two-thirds of gouty patients. Those who have not responded satisfactorily to uricosuric therapy are by and large patients who have some degree of renal insufficiency, or who continue to use salicylates concurrently, or who are intolerant of the drugs. It has been a goal in the therapy of gout to be able to regulate the production of uric acid, as well as its excretion. Experiments directed toward this goal have been conducted with azaserine by Zuckerman, Drell and Levin,l and with diazo-oxonorleucine by Grayzel, Seegmiller and Love.2 Both agents are glutamine antagonists and block an early reaction of purine synthesis. When these agents are administered to man the rate of production of uric acid is reduced and the levels of urate in serum and urine fall. The compounds are too toxic to be therapeutically useful in gout but the experiments are of interest. The pyrazolopyrimidines resemble the purines in structure except that nitrogen 7 and carbon 8 of the purine ring are reversed (Fig. 118). There are several pyrazolopyrimidine derivatives. The adenine analogue was explored as a cancer chemotherapeutic agent some time ago, with some preliminary success. When the studies were extended to man this compound proved to be hepatotoxic and its use was abandoned. 4-Hydroxypyrazolo ( 3,4-d)pyrimidine is an analogue of hypoxanthine which appeared to be biologically ineffective in tumor trials. It was shelved until recently when interest in its use as a xanthine oxidase inhibitor developed. Many purine analogues bind at the active site of xanthine oxidase and by this competitive mechanism inhibit the enzyme. The pyrazolopyrimidines were shown to be inhibitors of xanthine oxidase by Feigelson, Davidson and Robins." This demonstration rested in the literature for some time until the group at Burroughs Wellcome Laboratories became interested in the possible advantage of inhibiting xanthine oxidase in patients who were receiving 6-mercaptopurine as cancer chemotherapy. This latter compound is normally oxidized to 6-thiouric acid by xanthine oxidase. The question raised was whether one could provide a smoother chemotherapeutic course by giving a xanthine inhibitor together with 6-mercaptopurine ( 6-MP). Xanthine oxidase is the enzyme responsible for oxidation of hypoxanthine to xanthine, and of xanthine to uric acid (Fig. 119). These reactions are on the degradative side of purine nucleotide metabolism, so that inhibition of xanthine oxidase should not have any direct effect on nucleotide production, and nucleic acid metabolism. Figure 120 shows one of the early studies done by Dr. Wayne Rundles4 at Duke University in which he gave 6-mercaptopurine to a patient with chronic granulocytic leukemia, and determined the 883 ARTHRITIS AND RHEUMATISM, VOL. 8, NO. 5-PART 1 (OCTOBER), 1965
2 884 GOUT AND PURINE METABOLISM Adenine NH2 I 4-Aminopyrazolo(3,4-d)pyr imid ine NH2 I Hypoxanthine OH 4-Hydroxypyrazol0(3,4 -d)pyrimidine OH Fig Structural formulae of pyrazolo (3,4d) pyrimidines. XANTHINE OXIDASE Hypoxonthine Xonthine Uric Acid Fig Action of xanthine oxidase on oxypurines. amount which is excreted unchanged and the amount excreted as thiouric acid. Later the experiment was repeated after 300 mg. of hydroxypyrazolopyrimidine (HPP) had been given. In the second instance a larger percentage of 6-MP was excreted unchanged and the fraction converted to 6-thiouric acid was drastically reduced. Because of this effect on xanthine oxidase the question of what HPP would do to uric acid levels was raised. Appropriate study disclosed that the serum and urinary uric acid levels both fell and that there was a concomitant increase in the excretion of xanthine and hypoxanthine. The changes in this particular subject were not great but they indicated the desirability of extending these studies to other hyperuricemic patients, particularly those with gouts5z6 Figure 121 shows one of the gouty patients who was treated with HPP shortly thereafter. In this particular patient, who was asymptomatic at the time, the serum urate level of 6 to 7 mg. per cent was reduced by HPP to about 3 to 4 mg. per cent, and the urinary uric acid which was in the range of 600 mg./24 hours fell to between 200 and 300 mg./24 hours in about 5
3 XANTHINE OXIDASE INHIBITORS 885 e n x CHRONIC GRANULOCYTIC LEUKEMIA m o A Hgb VPRC WBC gm,/ yo x K.L.C. F URINE SERUk mercaptopurine. A Serum Uric Acid mg.% = o CHRONIC NON-TOPHACEOUS GOUT URINE W.R.B., F45318 Unrestricted Diet I :,,,, ;-y ~,!.,.,,,..,? 0=10/12/62 0 I i /
4 886 GOUT AND PURINE METABOLIShf Uric Uric Oxy Acid Acid purin % 24hrs. 24hi G.B.C., ACUTE GOUTY ARTHRITIS 14, W. Nightwatchman Subsiding Second Attack Treated With HPP Alone. I O= 3/28/63 Them ig/da y I ' 200 r--- Perform.Status %,I too 95 Fig Effect of large dose of HPP on urate levels in gouty subjects. days. There was an associated rise in oxypurine excretion. When the drug was discontinued the uric acid values returned to their previous levels. Figure 122 shows another gouty patient who was admitted for an attack of acute gouty arthritis. HPP was given in an initial dose of 900 mg./day. At that level his urinary uric acid fell from 1,OOO mg./24 hours to about 400 mg./24 hours and his serum uric acid from 8 or 10 mg. per cent to about 3 or 4 mg. per cent. With reduction of dosage an increase in urate levels occurred. Table 38 presents a summary of our first eight patient^.^ The Duke series now comprises 40 patients with gout, but the experience shown here is representative of the total group. In this group of patients the serum urate level was brought to or toward normal in from 5 to 20 days. With the drop of uricemia the urinary uric acid generally fell to an average of about half of previous levels. The dosage used ranged from 200 to 900 mg. per day. Oxypurine excretion increased in all patients. If xanthine oxidase inhibition were the only effect of HPP and renal function were good, the increase in hypoxanthine and xanthine excretions would be expected to balance the decrease in urate output. We have rarely found this. In our initial studies we may have encountered some loss of xanthine by precipitation from certain urine samples, and incomplete recoveries. We have since found that
5 XANTHINE OXIDASE INHIBITORS 887 Table 38.-Eflect of 4-Hydroxypyrazolopyrimidine (HPP) on Purine Metabolism in Gout Urine Urine Patient, No. HPP Days Serum Uric Acid Oxypurine Age, Race, Sex Diagnosis mg./day Rx Uric Acid mg./day mg./day H. C. S., A65086 Acute and , W, M Chr. Arth. 4U W. R. B.,F45318 Chronic , W, M arthritis M. N. B.,84618 Renal stones , W, M acute and Chr. Arth J. E. E..A?Z670 Severe Arth. 0 x = 40. W, M tophi x J. C. P.,F88837 Acute and * 59, w, M Chr. Arth nephropathy J. L. C., E22211 Chr. Arth , C, M tophi K. E. S.,F92133 Chr. Arth * 75, w, M tophi G. B. C., I nd acute , w, M attack *Constant Protein -Constant Purine ( Nutrament based) Diet. the balance may occasionally be nearly perfect in patients with good renal function immediately after HPP is given, but generally a major deficit of oxypurines does exist. In patients with renal damage or with marked tophaceous involvement the oxypurine increment/urate decrement ratio is generally well below 1, perhaps below 0.5. We have also observed a number of different kinds of response which suggest that total purine excretion may decline as a function of time. This may sometimes be a matter of depletion of stored urates but, curiously, the change may be in the oxypurines rather than in the urate, so that after some months the balance may not be the same as it was initially. Paper and column chromatographic analyses of urine have indicated that there are only trivial changes of other purine bases in the urine. One would not anticipate any major change of these on the basis of the action of the drug. We have observed a few patients who have not responded particularly well. In one patient, for example (Table 38, J. L. C.), with chronic tophaceous gout of severe degree and some limitation of renal function, who received 800 mg. of HPP per day, the serum urate level dropped from 9.3 mg. per cent to 7.2 mg. per cent, but the urinary uric acid actually increased, and there was only a modest increase in the urinary oxypurines. The atypical responses have, by and large, been in patients with tophaceous gout with some degree of renal involvement. We observed a few attacks of gout early in the period after HPP was started. In our first series of 14 subjects three had attacks in the first
6 888 GOUT AND PURINE METABOLISM 40 days. At that time we were giving HPP alone. It did not seem that the rate of attacks was any greater than it had been before therapy, but in some patients attacks of gout continued with about the established frequency. Because of this, we have subsequently added maintenance colchicine to the therapy of many subjects and the frequency of acute attacks has been far less. The acute attacks have occurred at serum levels well within the normal range; in fact we have observed attacks with serum levels as low as 2 mg. per cent. One patient was of particular interest. He had had gout for some years, with hypertension and renal involvement, and was not satisfactorily controlled by uricosuric therapy. He was given HPP and almost immediately began having staccato attacks of gout. These continued for about six weeks in spite of regulation of the urate level at 5 mg. per cent. It was necessary to terminate HPP therapy. On return to uricosuric therapy he has now had only one attack of any severity in about a year and a half. At the time we were unwilling to increase the dose of HPP to a level which might have brought his serum urate value lower, because we were uncertain whether we might have produced hyperxanthinemia of significant degree and whether he was now having a different type of gouty attack based on xanthine crystals rather than sodium urate crystals. We have subsequently measured the plasma oxypurine levels in patients receiving HPP. The normal values range from about 0.1 to 0.3 mg. per cent. During HPP therapy values have generally been around 0.4 and 0.5 mg. per cent. Others7g8 have seen values as high as 0.9 mg. per cent or rarely even 2 mg. per cent but xanthine levels certainly do not rise to match the uric acid levels that existed before therapy. The absence of a more dramatic rise of oxypurines apparently has its basis in a very high renal clearance of hypoxanthine and xanthine.9 One of the fears has been that the increase in urinary oxypurines might give rise to complications based on the insolubility of xanthine. The increment in oxypurines favors xanthine slightly; in our experience perhaps 55 to 60 per cent of the increase has been in xanthine. Hypoxanthine is a very soluble compound; one would not be much concerned about even very high levels of hypoxanthine in the urine, but xanthine is not very soluble in acid or neutral urine. Furthermore, the pk of xanthine is 7.7 compared with a pk of uric acid which is about 5.4. Alkalinization of the urine, therefore, would have to be carried to impractically high levels to have any appreciable effect on xanthine solubility. The urinary levels of xanthine that may be observed with HPP therapy approach those seen in xanthinuric subjects who form xanthine stones. In spite of this we have not seen any xanthine sludge or stones. We have watched for signs of toxicity very carefully, but have seen no increase in urinary sedimentary abnormalities in any of the patients treated. Three of some 60 patients who have received HPP for various reasons have shown minor signs of toxicity. In one case there was a skin rash, which did not recur when the drug was later restarted; another patient had a drug fever which did not recur when HPP was reinstituted;
7 XANTHINE OXIDASE INHIBITORS 889 and one patient had a transient drop in white count which did not recur when the drug was readministered. In all three of these instances the patients were receiving other compounds as well as HPP, and it was not certain in our minds that HPP was involved. Some patients had minimal gastric irritation at one time or another. This has not been a serious problem in our minds and DY. Rundles, who has been in the field of cancer chemotherapy for a long time and is very alert to the problems of intolerance and toxicity, is extremely sanguine about this compound up to this point. Our experience now ranges up to almost two and a half years. No really serious side effects have been observed during this time. Of course one must temper one s enthusiasm in recognition of the possibility of late toxic effects; for example, it is possible that this compound is incorporated into nucleic acids, although it is converted to a ribonucleotide so sparingly, at least in vitro, that it does not seem likely that much HPP is going to enter the nucleic acid pool. One might view this poor conversion to the ribonucleotide stage as unfortunate in one sense, because the ribonucleotide derivative is a very potent pseudo-feedback inhibitor of the first step of purine biosynthesis in 0itr0.l~ This inhibition may be an explanation for what appears to be a total reduction in rate of purine synthesis in some patients, but at the present time that is not certain. Perhaps reutilization of hypoxanthine and a resetting of the feedback by natural purine ribonucleotides also occur. ACKNOWLEDGMENTS Figures 118, 120, 121, 122, and Table 38 reprinted from Rundles et a14 with permission of the editor and publisher of the Transactions of the Association of American Physicians. 1. Zuckerman, R., Drell, W., and Levin, M. H.: Urinary Purines in Gout; Effect of Azaserine. Arth. il7 Rheumat. 2:46, Grayzel, A., Seegmiller, J. E., and Love, E.: Suppression of Uric Acid Synthesis in the Gouty Human by the Use of 6-diazo-5-0x0-L-norleucine. J. Clin. Invest. 39:447, Feigelson, P., Davidson, J. D., and Robins, R. K.: Pyrazolopyrimidines as Inhibitors and Substrates of Xanthine Oxidase. J. Biol. Chm. 226: 993, Rundles, R. W., Wyngaarden, J. B., Hitchings, G. H., Elion, G. B., and Silberman, H. R.: Effects of a Xanthine Oxidase Inhibitor on Thiopurine Metabolism, Hyperuricemia REFERENCES and Gout. Trans. Assn. of Am. Phys. LXXVI, 126: Wyngaarden, J. B., Rundles, R. W., Silberman, H. R., and Hunter, S.: Control of Hyperuricemia with Hydroxypyrazolopyrimidine, a Purine Analogue which Inhibits Uric Acid Synthesis. Arth Rundles, R. W., Silberman, H. R., Hitchings, G. W., and Elion, G. B.: Eftects of Xanthine Oxidase Inhibitor on Clinical Manifestations and Purine Metabolism in Gout. Ann. Int. Med. 60:717, Klinenberg, J. R., Goldfinger, S., Miller, J., and Seegmiller, J. E.: The Eff-ectiveness of a Xanthine Oxidase Inhibitor in the Treatment of Gout,
8 890 GOUT AND PURINE METABOLISM Arth. G Rheumat. 6:779, Yii, T. F., and Gutman, A. B.: Effect of Allopurinol (4-hydroxyppazolo (3,4- d)-pyrimidine) on Serum and Urinary Uric Acid in Primary and Secondary Gout. Am. J. Med. 37:885, Goldfinger, S., Klinenberg, J., and Seegmiller, J. E.: The Renal Excretion of Oxypurines. Clin. Res. 12:252, McCollister, R. J., Gilbert, W. R., Jr., Ashton, D. M., and Wyngaarden, J. B.: Pseudofeedback Inhibition of Purine Synthesis of 6-Mercaptopurine Ribonucleotide and other Purine Analogues. J. Biol. Chem. 239:1560, DR. SMYTH: We are all grateful to Dr. Wyngaarden for introducing for consideration this exciting new area for research in purine metabolism. I think it opens tremendous vistas for further exploration. One of the teams that has been in the forefront of this exciting field of exploration has been the group at the NIH, Dr. Klinenberg, Dr. Seegmiller and Dr. Goldfinger, who presented some of their preliminary studies in Boston in December, We would like to ask Dr. Klinenberg to bring us up to date on their experiences with this subject.
METABOLIC EFFECTS OF ALLOPURINOL AND ALLO-XANTHINE
Ann. rheum. Dis. (1966), 25, 615 METABOLIC EFFECTS OF ALLOPURINOL AND ALLO-XANTHINE BY R. W. RUNDLES From the Haematology Laboratory, Duke Hospital, and the Department of Medicine, Duke University School
More informationThe Renal Excretion of Oxypurines *
Journal of Clinical Investigation Vol. 44, No. 4, 1965 The Renal Excretion of Oxypurines * STEPHEN GOLDFINGER,t JAMES R. KLINENBERG,4 AND J. EDWIN SEEGMILLER (From the National Institute of Arthritis and
More informationSecondary Gout Associated with Myeloproliferative Diseases* imt. Sinai Hospital
Chapter VI Secondary Gout Associated with Myeloproliferative Diseases* By TS'AI-FAN Yu, M.D. imt. Sinai Hospital In a variety of disorders of hemopoiesis, the turnover of nucleic acids is greatly augmented,
More informationSESSION IV GOUT WITH RENAL COMPLICATIONS RENAL DAMAGE OF GOUT BIOCHEMICAL CONSIDERATIONS OF THE. Seegmiller, 1963). The type of crystal deposited is
Ann. rheum. Dis. (1966), 25, 668 SESSON V GOUT WTH RENAL COMPLCATONS (Chairman: DR. F. DUDLEY HART) BOCHEMCAL CONSDERATONS OF THE RENAL DAMAGE OF GOUT BY J. E. SEEGMLLER AND PAUL D. FRAZER From the Natio:ial
More informationNON-GOUTY URIC ACID NEPHROPATHY
Ann. rheum. Dis. (1966), 25, 673 EFFECTS OF ALLOPURINOL ON GOUTY AND NON-GOUTY URIC ACID NEPHROPATHY BY M. A. OGRYZLO, M. B. UROWITZ,* H. M. WEBER,* AND J. B. HOUPT From the University of Toronto Rheumatic
More informationCase presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg
GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies
More informationThe Effects of Azathioprine (Imuran) on Purine Synthesis
The Journal of Clinical Investigation Vol. 46, No. 9, 1967 The Effects of Azathioprine (Imuran) on Purine Synthesis in Clinical Disorders of Purine Metabolism * WILLIAM N. KELLEY, FREDERICK M. ROSENBLOOM,
More informationPRODUCT MONOGRAPH ZYLOPRIM. Allopurinol Tablets USP. 100, 200 and 300 mg. Xanthine Oxidase Inhibitor
0 PRODUCT MONOGRAPH Pr ZYLOPRIM Allopurinol Tablets USP 100, 200 and 300 mg Xanthine Oxidase Inhibitor AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 September 15, 2010 Vaughan, Ontario
More informationTREATMENT OF GOUT WITH ALLOPURINOL
Annz. rheium. Dis. (1966), 25, 627 TREATMENT OF GOUT WITH ALLOPURINOL A STUDY OF 106 CASES* BY F. DELBARRE, B. AMOR, C. AUSCHER, AND A. DE GERY Paris As allopurinol appears to be the most interesting of
More informationDrugs Used to Treat Gout. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used to Treat Gout Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Gout is a metabolic disease characterized by recurrent episodes of acute arthritis
More informationPRODUCT MONOGRAPH. Allopurinol Tablets USP. 100 mg, 200 mg and 300 mg. Xanthine Oxidase Inhibitor
1 PRODUCT MONOGRAPH Pr MAR-Allopurinol Allopurinol Tablets USP 100 mg, 200 mg and 300 mg Xanthine Oxidase Inhibitor Marcan Pharmaceuticals Inc. Date of Preparation: 77 Auriga Drive, Unit # 4 March 15,
More informationuric acid Non electrolytes of the plasma
73 uric acid Non electrolytes of the plasma 1 Purines and uric acid Fig 2 JFI Uric acid is the major product of catabolism of the purine nucleosides adenosine and guanosine, Uric acid is sparingly soluble
More informationClinical Biochemistry department/ College of medicine / AL-Mustansiriyah University
Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Dr. Ali al-bayati NUCLEOTIDE METABOLISM Lec. 3 The salvage pathway of purine synthesis Purines that result from the normal
More informationSUCCESSFUL TREATMENT OF GOUT*
SUCCESSFUL TREATMENT OF GOUT* By ELMER C. BARTELS, M.D., F.A.C.P., Boston, Massachusetts GOUT has received widespread publicity during the last 10 years, with most writers giving attention to all the various
More informationUrate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout
Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.
More informationPRODUCT MONOGRAPH ZYLOPRIM. Allopurinol Tablets USP. 100, 200 and 300 mg. Xanthine Oxidase Inhibitor
PRODUCT MONOGRAPH Pr ZYLOPRIM Allopurinol Tablets USP 100, 200 and 300 mg Xanthine Oxidase Inhibitor AA PHARMA INC. DATE OF REVISION: 1165 Creditstone Road, Unit #1 January 17, 2017 Vaughan, Ontario L4K
More informationDESCRIPTION: ZYLOPRIM (allopurinol) has the following structural formula:
100-mg Scored Tablets and 300-mg Scored Tablets PRODUCT INFORMATION Rx Only DESCRIPTION: ZYLOPRIM (allopurinol) has the following structural formula: ZYLOPRIM is known chemically as 1,5-dihydro-4H-pyrazolo
More informationMetabolism of Nucleotides
Metabolism of Nucleotides Outline Nucleotide degradation Components of Nucleobases Purine and pyrimidine biosynthesis Hyperuricemia Sources Nucleotide degradation The nucleotides are among the most complex
More informationPRODUCT MONOGRAPH. allopurinol tablets, USP. 300 mg. Xanthine oxidase inhibitor. Submission Control No:
PRODUCT MONOGRAPH Pr ALLOPURINOL allopurinol tablets, USP 300 mg Xanthine oxidase inhibitor APOTEX INC. DATE OF REVISION: 150 Signet Drive January 17, 2017 Toronto, Ontario M9L 1T9 Submission Control No:
More informationNUCLEOTIDE METABOLISM
NUCLEOTIDE METABOLISM Purine and pyrimidine. The atoms are numbered according to the international system. Tautomerism of the oxo and amino functional groups of purines and pyrimidines. POLYNUCLEOTIDES
More informationCoulter Countei Model FN
BLOOD: THE JOURNAL OF HEMATOLOGY Xxxiii Now, platelet counts, too... they re standard with the new Coulter Countei Model FN This is the Coulter Counter Model EN, a recent innovation resulting from Coulter
More informationThe Treatment of Gout
DRUG LETTER The Treatment of Gout Stanley L. Wallace Gout is usually the most treatable of the arthritides. Acute attacks, if caught early enough, can 'be eradicated rapidly and completely. Recurrences
More information1. To review the diagnosis of gout and its differential. 2. To understand the four stages of gout
Objectives 1. To review the diagnosis of gout and its differential GOUT 2. To understand the four stages of gout 3. To develop an approach for the acute treatment of gout Anthony Lim 9/13/12 Cycle 3 4.
More informationNucleotide Metabolism Biochemistry by Lippincott pp
Nucleotide Metabolism Biochemistry by Lippincott pp 291-306 Deoxyribonucleotides Synthesis 2'-deoxyribonucleotides: Nucleotides required for DNA synthesis Produced from ribonucleoside diphosphates by ribonucleotide
More informationStudy of the Utilization and Excretion of Dietary Purines
Journal of Clinical Investigation Vol. 45, No. 12, 1966 Study of the Utilization and Excretion of Dietary Purines in a Xanthinuric Man * JOHN H. AYVAZIAN t AND SOLOMON SKUPP (From the Medical and Research
More informationGout -revisited. Shrenik Shah
Gout -revisited Shrenik Shah definition Monosodium urate (MSU) crystal deposition episodic and later persistent joint inflammation and tophi All MSU crystal deposition- broader definition EULAR- European
More informationAllopurinol inhibits xanthine oxidase, the enzyme which catalyses the conversion of hypoxanthine to xanthine, and of xanthine to urate/uric acid.
Progout Allopurinol PRODUCT INFORMATION Name of the Medicine The active ingredient of Progout tablets is allopurinol. Chemical name: 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one. Structural formula: Molecular
More informationGout 2.0. Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy
Gout 2.0 Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy Case 48 year old man presents with swollen, painful left toe that started overnight. Didn t hurt when he went to bed. No
More informationUrea cycle: Urea cycle is discovered by Krebs andhanseleit(1932).
Urea cycle: Urea cycle is discovered by Krebs andhanseleit(1932). Urea cycle is the removal of excess of NH2 derived from amino acids catabolism in the tissues and excreted in urine. Site of synthesis:
More informationTERRY WHITE ALLOPURINOL
TERRY WHITE ALLOPURINOL NAME OF THE MEDICINE Allopurinol. Chemical Name: 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one. Chemical Structure: Molecular Formula: C 5 H 4 N 4 O Molecular Weight: 136.1 CAS
More informationGout A rapid review. Jeremy Jones
Gout A rapid review Jeremy Jones The Hyperuricemia Cascade Dietary purines Tissue nucleic acids Urate Endogenous purine synthesis Overproduction Hyperuricemia Underexcretion Silent tissue deposition Gout
More informationUpdate on Gout for GPs
Update on Gout for GPs Dr Patrick Kiely PhD FRCP Consultant Physician and Rheumatologist St George s, London 2/3 1/3 Gut bacteria have uricase Chronic erosive arthropathy Clinical spectrum Making the diagnosis
More informationCost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout
Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout The NCPE has issued a recommendation regarding the cost-effectiveness of Lesinurad (Zurampic ) in combination with
More informationNucleotide Metabolism. Pyrimidine Met. Purine Met.
Nucleotide Metabolism Pyrimidine Met. Purine Met. Learning Objectives 1. How Are Purines Synthesized? 2. How Are Purines Catabolized? 3. How Are Pyrimidines Synthesized and Catabolized? 4. How Are Ribonucleotides
More informationrenal disposal of urate through deposition in tophi or increased uricolysis The purpose of the present investigation was
By J. E. SEEGMILLER, ARTHUR I. GRAYZEL, LEONARD LASTER AND LOIS LIDDLE (From the National Institute of Arthritis and Metabolic Diseases, Bethesda, Md.) (Submitted for publication September 2, 196; accepted
More informationCHAPTER:2 GOUT. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:2 GOUT BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY DEFINITION Gout is defined as a peripheral arthritis, resulting from the deposition of MSU crystals
More informationPRODUCT INFORMATION Progout Allopurinol NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Active ingredient : Allopurinol
PRODUCT INFORMATION Progout Allopurinol NAME OF THE MEDICINE Active ingredient : Allopurinol Chemical name : 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one Structural formula : Molecular formula : C 5H
More informationEssence of the Revised Guideline for the Management of Hyperuricemia and Gout
Research and Reviews Essence of the Revised Guideline for the Management of Hyperuricemia and Gout JMAJ 55(4): 324 329, 2012 Hisashi YAMANAKA,* 1 The Guideline Revising Committee of Japanese Society of
More informationMDSC 1102/VM1102 Cardiovascular and Renal. Purine nucleotide metabolism
MDSC 1102/VM1102 Cardiovascular and Renal Purine nucleotide metabolism Dr. J. Foster Biochemistry Unit, Dept. Preclinical Sciences Faculty of Medical Sciences, U.W.I. Learning Objectives Discuss purineand
More informationNon-protein nitrogenous substances (NPN)
Non-protein nitrogenous substances (NPN) A simple, inexpensive screening test a routine urinalysis is often the first test conducted if kidney problems are suspected. A small, randomly collected urine
More informationGOUT disease spectrum including
GOUT disease spectrum including *hyperuricemia, *recurrent attacks of acute arthritis associated with monosodium urate crystals in leukocytes found in synovial fluid, *deposits of monosodium urate crystals
More informationNew Zealand Data Sheet ALLOPURINOL-APOTEX
New Zealand Data Sheet ALLOPURINOL-APOTEX Presentation ALLOPURINOL-APOTEX 100mg tablets are white to off white, round, biconvex, uncoated tablets, engraved AL and 100 separated by breakline on one side
More informationGout. Clinical features Most commonly affects middle-aged males. It is an acute and usually relapsing selflimiting
Gout Gout is a syndrome caused by an inflammatory response to the formation of monosodium urate monohydrate crystals which develop secondary to hyperuricemia. Acute and chronic forms are recognized. Hyperuricemia
More informationALLOPURINOL IN THE TREATMENT OF URAEMIC PATIENTS WITH GOUT*
Ann. rheum. Dis.' 1967), 26, 136 ALLOPURINOL IN THE TREATMENT OF URAEMIC PATIENTS WITH GOUT* BY J. D. WILSON, H. A. SIMMONDS, AND J. D. K. NORTH From the Medical Unit, Auckland Hospital, Auckland, New
More informationGout- Treatment Updates. Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA
Gout- Treatment Updates Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA Gout Outline of purine metabolism: (1) amidophosphoribosyltransferase (2) hypoxanthine-guanine phosphoribosyltransferase
More informationTumor Lysis Syndrome Nephrology Grand Rounds Tuesday, July 27 th, 2010 Aditya Mattoo
Tumor Lysis Syndrome Nephrology Grand Rounds Tuesday, July 27 th, 2010 Aditya Mattoo Outline Background/Definition Epidemiology/Risk Stratification Pathophysiology Treatment Renal Replacement Therapy Background/Definition
More informationUloric Step Therapy Program
Uloric Step Therapy Program Policy Number: 5.01.584 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for brand
More informationDrugs for Gout, osteoarthritis and osteoporosis
MMS Pharmacology Lecture 3 Drugs for Gout, osteoarthritis and osteoporosis Dr Sura Al Zoubi Revision Gout The term gout describes a disease spectrum including hyperuricemia, recurrent attacks of acute
More informationAchieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP
Achieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP Dr. Paul Doghramji is attending physician at the Pottstown Memorial Medical Center and medical director of Health Services
More informationCOMPARATIVE EVALUATION OF EFFICACY AND SAFETY PROFILE OF FEBUXOSTAT WITH ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND GOUT
Int. J. Pharm. Med. & Bio. Sc. 2013 P K Agarwal and Bijay Kumar, 2013 Research Paper ISSN 2278 5221 www.ijpmbs.com Vol. 2, No. 4, October 2013 2013 IJPMBS. All Rights Reserved COMPARATIVE EVALUATION OF
More informationSchool of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR
1 School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR URINARY (RENAL) STONE FORMATION An Overview What are Urinary (Renal)
More informationACP Rheumatology Pearls. Adam Q Carlson MD Assistant Professor UVA Rheumatology
ACP Rheumatology Pearls Adam Q Carlson MD Assistant Professor UVA Rheumatology Disclosures I have no personal or professional disclosures Case #1 27 yo woman with a history of systemic lupus complicated
More informationNyperuricemia Induced by Drugs
Nyperuricemia nduced by Drugs By FELX E. DEMARTN, M.D. Columbia University College of Physicians and Surgeons Alterations in the physiological mechanisms regulating the metabolism of purines obviously
More informationMechanism of Excessive Purine Biosynthesis in Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency
Mechanism of Excessive Purine Biosynthesis in Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency LEIF B. SORENSEN From the Department of Medicine, the Pritzker School of Medicine, University of
More informationQuestions on Purine and Pyrimidine Metabolism:
Questions on Purine and Pyrimidine Metabolism: 1. Mention the Origin of Carbon and itrogen Atom in Purine Ring. (2) 2. Sources of various atoms of purine ring. (4) 3. Give an account on salvage pathway.
More informationLECTURE 5: DRUGS IN GOUT
Red : important Black : in male / female slides Pink : in female s slides only Blue : in male s slides only Green : Dr s notes Grey: Extra information, explanation Editing File LECTURE 5: DRUGS IN GOUT
More informationspecimens drawn 24, 48 and 72 hours after the
A STUDY OF THE HYPERURICEMIA INDUCED BY HYDRO- CHLOROTHIAZIDE AND ACETAZOLAMIDE SEPA- RATELY AND IN COMBINATION * By JOHN H. AYVAZIAN t AND L. FRED AYVAZIAN (From the Department of Medicine, New York University
More informationA STUDY OF THE METABOLISM OF THEOBROMINE, THEOPHYLLINE, AND CAFFEINE IN MAN* Previous studies (1, 2) have shown that after the ingestion of caffeine
A STUDY OF THE METABOLISM OF THEOBROMINE, THEOPHYLLINE, AND CAFFEINE IN MAN* BY HERBERT H. CORNISH AND A. A. CHRISTMAN (From the Department of Biological Chemistry, Medical School, University of Michigan,
More informationZurampic. (lesinurad) New Product Slideshow
Zurampic (lesinurad) New Product Slideshow Introduction Brand name: Zurampic Generic name: Lesinurad Pharmacological class: URAT1 inhibitor Strength and Formulation: 200mg; tablets Manufacturer: Ironwood
More informationGout: Update in therapeutics
Summary Gout: Update in therapeutics 29/11/14 Caroline van Durme CHU de Liège Maastricht University Medical Centre+ Why treating gout? Guidelines: ACR 12 Drugs: Colchicine Allopurinol: what about the kidney?
More informationnumber Done by Corrected by Doctor
number 35 Done by حسام ا بوعوض Corrected by عبدالرحمن الحنبلي Doctor Diala 1 P age We mentioned at the end of the last lecture that ribonucleotide reductase enzyme can be inhibited preventing the synthesis
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationPRODUCT INFORMATION. ALLOSIG (allopurinol) Tablets H N N NH
PRODUCT IFORMATIO ALLOSIG (allopurinol) Tablets AME OF THE MEDICIE ALLOSIG tablets contain 100 mg or 300 mg allopurinol. DESCRIPTIO Chemical Structure H H H OH O Chemical ame: 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one.
More informationRelationship between plasma oxipurinol concentrations and
Br. J. clin. Pharmac. (1988), 26, 429-434 Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol R. 0. DAY, J. MINERS, D. J. BIRKETT, G.
More informationDrugs Used in Gout. Knox Van Dyke. GENERIC NAME Allopurinol 445 Colchicine 443 Indomethacin 446 Oxyphenbutazone 446
37 Drugs Used in Gout Knox Van Dyke DRUG LIST GENERIC NAME PAGE GENERIC NAME PAGE Allopurinol 445 Colchicine 443 Indomethacin 446 Oxyphenbutazone 446 Oxypurinol 446 Phenylbutazone 446 Probenecid 445 Sulfinpyrazone
More informationgouty subjects, and the concentration and cumulative
OVERPRODUCTION OF URIC ACID AS THE CAUSE OF HYPERURICEMIA IN PRIMARY GOUT BY JAMES B. WYNGAARDEN (From the Department of Medicine, Duke University School of Medicine, Durham, N. C., and the National Institute
More informationLecture 8 Gout Hinch. Pathogenesis of acute attacks
Gout: disease characterized by deposition of monosodium crystals in soft tissues (cartilage, tendons, bursa) recurrent episodes of acute joint pain & inflammation Pathogenesis of acute attacks Epidemiology:
More informationAn update on the management of gout
An update on the management of gout 8 The management of gout involves treatment of an acute attack, lifestyle modification and urate lowering treatment to achieve a target serum urate level. Recent evidence
More informationafter two weeks' treatment. (This order of dose is usually necessary to achieve an adequate uricosuric response.) Of the
6 August 1966 BRemH 1 Papers Originals in Treatment of Gout J. T. SCOYT,*t M.B., M.R.C.P.; A. P. HALL,*: M.B., M.R.C.P.; R. GRAHAME,* M.B., M.R.C.P. Brit. med. J., 1966,, 1-7 (4-hydroxypyrazolo (,4-d)
More informationAllopurinol treatment and its effect on renal function
Annals of the Rheumatic Diseases, 1982, 41, 59-65 Allopurinol treatment and its effect on renal function in gout: a controlled study T. GIBSON, V. RODGERS, C. POTTER, AND H. A. SIMMONDS From the Departments
More informationAnalgesics. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine The University of Jordan March, 2014
Analgesics Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine The University of Jordan March, 2014 Mar-14 Munir Gharaibeh, MD, PhD, MHPE 2 Feature Comparison of Analgesics Narcotic (Opioids) Nonnarcotic
More informationLimitations of Use: (1) Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.63 Subject: Duzallo Page: 1 of 5 Last Review Date: December 8, 2017 Duzallo Description Duzallo (lesinurad
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationEducation and Welfare, Bethesda, Md.) The present report deals with the effect of. G on the simultaneous renal clearances of
EFFECT OF A PHENYLBUTAZONE ANALOG (4-[PHENYLTHIOETHYL]-1,2- DIPHENYL 3,5-PYRAZOLIDINEDIONE) ON URATE CLEARANCE AND OTHER DISCRETE RENAL FUNCTIONS IN GOUTY SUBJECTS. EVALUATION AS URICOSURIC AGENT 1 By
More informationMechanism of Allopurinol -Mediated Increase
Mechanism of Allopurinol -Mediated Increase in nzyme Activity in Man THOMAS D. BARDMOR, JAY S. CASHMAAN, and WILLIAM N. KLLY From the Division of Rheumatic and Genetic Diseases, Department of Medicine,
More informationX sible for the oxidation of hypoxanthine
Effects of Allopurinol, a Xanthine Oxidase Inhibitor, and Sulfinpyrazone upon the Urinary and Serum Urate Concentrations in Eight Patients with Tophaceous Gout By EDWAW GOLDFAHB AND CHARLEY J. SMYTH ANTHINE
More informationEvidence for a Postsecretory Reabsorptive
Evidence for a Postsecretory Reabsorptive Site for Uric Acid in Man HERBERT S. DIAumoi and JAMEs S. PAOLINO From the Department of Medicine, State University of New York Downstate Medical Center, Brooklyn,
More informationPRELIMINARY CRITERIA FOR THE CLASSIFICATION OF THE ACUTE ARTHRITIS OF PRIMARY GOUT
895 PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF THE ACUTE ARTHRITIS OF PRIMARY GOUT STANLEY L. WALLACE, HARRY ROBINSON, ALFONSE T. MASI, JOHN L. DECKER, DANIEL J. McCARTY. and T SAI-FAN Yo The American
More informationAUSTRALIAN PRODUCT INFORMATION ALLOPURINOL APOTEX (ALLOPURINOL) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
AUSTRALIAN PRODUCT INFORMATION ALLOPURINOL APOTEX (ALLOPURINOL) 1 NAME OF THE MEDICINE Allopurinol 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM Allopurinol is a white or off-white,
More informationOBJECTIVES GOUT GOUTY INFLAMMATION 6/10/2016 GOUT INCIDENCE AND PREVALENCE MONOSODIUM URATE CRYSTAL DEPOSITION DISEASE
GOUT Lisa Talbert, MD Family Medicine Update June 15, 2016 OBJECTIVES To be familiar with the clinical presentation and pathophysiology of gouty arthritis Be able to incorporate current guidelines when
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Uric acid GUIDELINES. No recommendations possible based on Level I or II evidence.
Date written: July 2004 Final submission: July 2004 Author: David Johnson Uric acid GUIDELINES No recommendations possible based on Level I or II evidence. SUGGESTIONS FOR CLINICAL CARE (Suggestions are
More informationPart I: On-line web-based survey of Dalmatian owners GENERAL INFORMATION
Dr. Bartges' final report on the Dal stone survey: Commissioned by the Dalmatian Club of America Foundation (DCAF) Published in the DCA magazine, The Spotter, Summer 2006 Part I: On-line web-based survey
More informationStudy of Febuxostat for the Management of Hyperuricemia in Gout
Human Journals Review Article October 2015 Vol.:4, Issue:3 All rights are reserved by Sachin S. Shinde et al. Study of Febuxostat for the Management of Hyperuricemia in Gout Keywords: Febuxostat, Hyperuricemia,
More informationLesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout
Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout Briefing Document for the Arthritis Advisory Committee Meeting Date: 23 October 215 Ardea
More informationDr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.
The uric acid dilemma: causal risk factor for hypertension and CKD or mere bystander? Mehmet Kanbay, Istanbul, Turkey Chairs: Anton H. van den Meiracker, Rotterdam, The Netherlands Claudia R.C. Van Roeyen,
More informationFor more information about how to cite these materials visit
Author(s): Seetha Monrad, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationLESSON ASSIGNMENT. Analgesic, Anti-Inflammatory, and Antigout Agents.
LESSON ASSIGNMENT LESSON 4 Analgesic, Anti-Inflammatory, and Antigout Agents. TEXT ASSIGNMENT Paragraphs 4-1 through 4-8. LESSON OBJECTIVES 4-1. Given one of the following terms: analgesic, antipyretic,
More informationGout Treatment Guidelines
Gout Treatment Guidelines Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a foundation of an excess body burden of uric acid, manifested in part by hyperuricemia,
More informationUpdate on Gout. It s important for D.P.M. s to understand this acute metabolic disease.
CLINICAL PODIATRY Goals To provide the podiatrist with information regarding gout and its therapy. Objectives After reading this article, the podiatrist should be able to do the following: 1) Identify
More informationNew Drug Evaluation: lesinurad tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCrystal induced arthropathies. Dr. Amitesh Aggarwal
Crystal induced arthropathies Dr. Amitesh Aggarwal 1 Crystal induced Arthropathies Gout Pseudogout Debilitating illnesses; Recurrent episodes of pain and joint inflammation; Formation and deposition of
More informationA Patient s Guide to Gout. Foot and Ankle Center of Massachusetts, P.C.
A Patient s Guide to Gout Welcome to Foot and Ankle Center of Massachusetts, where we believe in accelerating your learning curve with educational materials that are clearly written and professionally
More informationGout Prevention Project. Simplifying Gout Prevention Management for GPs and Patients
Gout Prevention Project Simplifying Gout Prevention Management for GPs and Patients Gout Prevalance 2 Gout Management primary care level 52.8% of PCP provided optimal medication treatment for acute attack
More informationRheumatology Cases for the Internist
Rheumatology Cases for the Internist Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of Rheumatology and Clinical Immunology Vice Chair, Department of Medicine University of Maryland School
More informationNucleotide metabolism
Nucleotide metabolism Dr. Diala Abu-Hassan, DDS, PhD Medical students-first semester All images are taken from Lippincott s Biochemistry textbook except where noted Purine and pyrimidine structures and
More informationFebuxostat now subsidised on Special Authority
Gout update: Febuxostat now subsidised on Special Authority 38 Febuxostat was added to the New Zealand Pharmaceutical Schedule on 1 June, 2014. It is now available as a third-line preventive treatment
More informationCLINICAL BIOCHEMISTRY 6 PLASMA PROTEINS AND PATHOLOGICAL IMPLICATIONS OF THEIR IMBALANCE
LINIAL BIOHEMISTRY 6 PLASMA PROTEINS AND PATHOLOGIAL IMPLIATIONS OF THEIR IMBALANE DISTURBANES OF PROTEIN METABOLISM NPN result from the metabolism of aminoacids, proteins, nucleic acids 2.3.1. UREA (75%
More informationEffect of oral fructose on urate production
Ann. rheuim. Dis. (1974), 33, 276 Effect of oral fructose on urate production B. T. EMMERSON From the University of Queensland Department of Medicine at the Princess Alexandra Hospital, Woolloongabba,
More information